With mid-stage AML win, Kura details dual-track Phase III program for ziftomenib

Kura Oncology is gearing up to stake a claim in the heated battleground for menin inhibitors to treat acute myeloid leukaemia (AML), announcing Wednesday that its drug ziftomenib — partnered with Kyowa Kirin — met the primary endpoint in a key trial, while unveiling plans for a Phase III programme in newly diagnosed patients.